Clinical trial · Interventional
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
Phase II Trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
NCT06045195CI-TRIAL-00088219Pembro-FLASHnot yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment
- description
- Pembrolizumab + BrECADD
- interventionNames
- Drug: Pembrolizumab
Primary outcomes (1)
- measure
- progression free survival
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Main Inclusion Criteria: * age 18-60 * advanced stage classical Hodgkin Lymphoma * no previous treatment for cHL Main Exclusion Criteria: * Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma * Chemotherapy or radiotherapy in medical history * Prior or concurrent disease that prevents treatment according to protocol
References
Publications (0)
Data not yet available
No reference posted for this study.